{"id":"tozinameran-bnt162b2","rwe":[],"tags":[],"safety":{"commonSideEffects":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tozinameran-bnt162b2","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:30:39.154368+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T07:29:11.814203+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650429/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:29:05.416195+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:29:13.245978+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:30:44.649745+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T07:29:04.479966+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:29:13.245961+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:29:13.245959+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Spike glycoprotein vaccine antigen","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:30:46.506141+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650429/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:30:46.175547+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:29:13.245903+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:29:13.245929+00:00"}},"allNames":"tozinameran (bnt162b2)","offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"S","drugClass":"mRNA vaccine","explanation":"Tozinameran delivers genetic instructions to cells, which then produce the coronavirus spike protein. This prompts the body to develop antibodies and immune memory against the virus, protecting against COVID-19.","oneSentence":"Tozinameran (BNT162b2) is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response."},"_scrapedAt":"2026-03-27T23:28:22.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"chemblData":{"prodrug":0,"chemblId":"CHEMBL4650429","maxPhase":"4.0","chirality":1,"parenteral":false,"availability":-1,"moleculeType":"Vaccine component","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"fdaRecalls":[],"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T07:29:11.940084+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL4650429"},"formularyStatus":[],"_approvalHistory":[],"chemblMechanisms":[{"actionType":"VACCINE ANTIGEN","targetChemblId":"CHEMBL4662936","mechanismComment":null,"mechanismOfAction":"Spike glycoprotein vaccine antigen"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"_revenueScrapedAt":"2026-04-01 10:46:06.083601+00","biosimilarFilings":[],"_revenueClearedDupe":"famtozinameran-12-years-of-age-and-older","participantFlowData":[],"companionDiagnostics":[],"structuredTrialResults":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Tozinameran (BNT162b2)","genericName":"tozinameran-bnt162b2","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T07:29:11.940084+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}